Rosacea Treatment Guide

What Is Rosacea?

Rosacea is a chronic inflammatory skin condition that primarily affects the central face — the cheeks, nose, chin, and forehead. Estimates suggest it affects roughly 5–10% of the global population, with higher rates in people of Northern European ancestry and in those with fair skin (Fitzpatrick types I–II). Women are diagnosed more often, but men tend to develop more severe manifestations, including the disfiguring skin changes of rhinophyma.^[1]

Rosacea follows a relapsing course. Patients cycle through periods of flare and relative calm, often triggered by identifiable environmental or lifestyle factors. Left unmanaged, the condition tends to progress over years — persistent redness can become permanent, and inflammatory papules can recur more frequently. Starting treatment early gives you the best chance of keeping the disease under good control.

In my practice, rosacea patients often arrive frustrated, having tried over-the-counter products for months. The key shift in understanding is this: rosacea is not a cosmetic problem you can treat with more moisturizer. It is an inflammatory vascular disease that requires targeted medical management.

The Four Subtypes of Rosacea

The 2002 National Rosacea Society (NRS) classification described four subtypes based on the predominant clinical features. These remain a useful framework for organizing what you see, even as current guidelines have moved toward a more flexible phenotype-based approach.^[2]

Subtype 1: Erythematotelangiectatic (ETR)

This is the most common subtype, characterized by persistent central facial redness and a history of recurrent flushing or blushing. You may notice visible small blood vessels (telangiectasia) under the skin surface, particularly around the nose and cheeks. The skin often burns, stings, or feels tight, especially after temperature changes. Wind, sun, hot beverages, and emotional stress are frequent triggers. In darker skin tones, the redness may appear as a brown or purple discoloration rather than a classic red flush.

Subtype 2: Papulopustular

Papulopustular rosacea features persistent central facial redness accompanied by transient acne-like papules (red bumps) and pustules (pus-filled bumps). This subtype is commonly misidentified as acne, but there is a critical distinguishing feature: rosacea never produces blackheads or whiteheads (comedones). The bumps in papulopustular rosacea are superficial and spread beyond the follicle, whereas acne originates inside the hair follicle.^[5] Perioral and perinasal involvement can occur, and burning or stinging sensations are common.

Subtype 3: Phymatous

Phymatous rosacea involves progressive skin thickening, irregular nodularities, and enlargement of affected areas. Rhinophyma — enlargement and irregular thickening of the nose — is the most recognizable form. Phymatous changes can also affect the chin (gnathophyma), forehead (metophyma), cheeks, and ears. This subtype occurs more often in men and tends to develop after years of inadequately treated ETR or papulopustular disease. Early treatment with low-dose doxycycline or isotretinoin can slow progression; established rhinophyma requires laser or surgical correction.

Subtype 4: Ocular Rosacea

Ocular rosacea affects the eyes and eyelids and is present in up to 58% of rosacea patients — yet it remains one of the most frequently overlooked subtypes. In roughly 15–20% of cases, eye symptoms appear before any skin changes develop, which often leads to years of misdiagnosis and inadequate treatment.^[8] Symptoms include a gritty or foreign body sensation in the eye, eyelid redness and telangiectasia, crusting along the lash line, recurring chalazia (styes), and chronic dry eye from meibomian gland dysfunction. Corneal involvement can occur in severe cases and requires urgent ophthalmology referral.

The Shift to Phenotype-Based Management

In 2017, the NRS Expert Committee updated the rosacea classification system to move away from rigid subtype labels toward a phenotype-based approach. The reasoning was straightforward: most patients have overlapping features, and treatment should target the specific signs and symptoms present — not a subtype category.^[1]

Under this framework, clinicians assess each of the following phenotypes and assign treatment accordingly:

• Fixed centrofacial erythema (diagnostic criterion)
• Phymatous changes (also diagnostic)
• Papules and pustules (major feature)
• Flushing/transient erythema (major feature)
• Telangiectasia (major feature)
• Ocular manifestations (major feature)
• Burning or stinging, edema, dry appearance (secondary features)

A diagnosis of rosacea requires either one diagnostic criterion or two major features. What this means practically is that I assess each patient as an individual — a person with primarily persistent redness will receive different therapy than someone whose main complaint is inflammatory papules, even if they technically fall under the same "subtype."

Topical Medications

Topical treatments carry the highest level of evidence in rosacea management and are the first line of therapy for most patients with mild to moderate disease.^[1]

Ivermectin 1% Cream (Soolantra)

Ivermectin 1% cream is applied once daily and targets inflammatory papules and pustules of moderate to severe papulopustular rosacea. It is the most effective topical option currently available for this phenotype. In head-to-head trials against metronidazole 0.75%, ivermectin produced significantly greater reductions in lesion count, higher Investigator Global Assessment success rates, and better quality-of-life scores.^[6] It works through two mechanisms: a direct anti-parasitic effect that reduces Demodex mite density on the skin, and an anti-inflammatory effect that downregulates pro-inflammatory mediators including TLR-4, IL-8, and TNF-α. Well-tolerated; skin irritation is uncommon.

Metronidazole 0.75% and 1%

Metronidazole has decades of evidence behind it and remains a reliable option for papules, pustules, and background erythema. Available as a cream, gel, or lotion in 0.75% and 1% formulations, applied once or twice daily. It works primarily through anti-inflammatory mechanisms — inhibiting oxidative stress pathways in the skin rather than killing bacteria per se. It is an appropriate first-line choice for mild papulopustular disease and works well in combination with a gentle cleanser and broad-spectrum sunscreen.^[3]

Azelaic Acid 15% (Finacea)

Azelaic acid 15% gel or foam, applied twice daily, reduces both inflammatory papules and background redness by inhibiting reactive oxygen species and NADPH oxidase activity in the skin. In some comparisons it has outperformed metronidazole for erythema reduction. It is a good option for patients who want to treat both the bumps and the redness with a single product. Mild skin stinging is the most common side effect, typically fading after the first few weeks of use.^[1]

Brimonidine Gel 0.33% (Mirvaso)

Brimonidine is an alpha-2 adrenergic agonist that causes direct vasoconstriction of superficial facial blood vessels. It is used specifically for persistent facial redness — it has no effect on papules or telangiectasia. Applied once daily or as needed, it begins working within 30 minutes and the effect lasts roughly 8–12 hours. About 58% of patients show a meaningful reduction in erythema by day 29.^[1] A clinically important caution: some patients experience rebound erythema — a temporary worsening of redness after the medication wears off. Use with caution in patients with cardiovascular insufficiency or Raynaud's phenomenon.

Oral Medications

Low-Dose Doxycycline 40 mg Modified-Release (Oracea)

Oracea is the only FDA-approved oral treatment for the inflammatory lesions of rosacea. At 40 mg in a modified-release formulation, doxycycline works as an anti-inflammatory — serum levels stay below the threshold required for antimicrobial activity, which means it reduces inflammation without selecting for antibiotic-resistant bacteria. This is a key advantage over full-dose antibiotic courses.^[4]

In clinical trials, 40 mg modified-release doxycycline reduced inflammatory lesion counts significantly at 16 and 52 weeks, with relapse rates lower than placebo even after stopping. Side effects are similar to placebo at this dose — far fewer GI complaints than standard doxycycline 100 mg. Take it in the morning with a full glass of water, and avoid lying down for at least 30 minutes to prevent esophageal irritation.

What I tell patients: this is not a short course of antibiotics. For most people, it is a maintenance medication used for months — sometimes years — alongside a topical agent.

Oral Isotretinoin

Isotretinoin is reserved for severe or refractory rosacea — cases that have not responded adequately to topical therapy and low-dose doxycycline, or patients with significant phymatous changes. It is effective across all rosacea phenotypes, including for reducing sebaceous gland hyperplasia that contributes to rhinophyma. Doses used in rosacea (0.25–0.5 mg/kg/day or lower "microdose" regimens of 0.04–0.11 mg/kg) are generally lower than those used for acne.^[1]

Isotretinoin requires enrollment in the iPLEDGE risk management program due to its teratogenicity. Monthly lab monitoring for liver enzymes and lipids, plus regular office visits, are required. This is not a medication to be started over telehealth — it needs in-person dermatology management. Referral is appropriate for any patient in this category.

The Demodex Connection

Demodex folliculorum is a microscopic mite that lives in the hair follicles and sebaceous glands of most human adults — it is a normal inhabitant of healthy skin. In rosacea patients, however, these mites are present at 15–18 times the density found in unaffected individuals.^[6]

The mechanisms linking Demodex to rosacea inflammation are an active area of research. The current model suggests several pathways: the mites physically block follicular openings, triggering an inflammatory response; their bacterial co-inhabitants (including Bacillus oleronius) release proteins that activate immune pathways; and Demodex antigens stimulate Toll-like receptor 2 (TLR-2) on keratinocytes, amplifying the innate immune response already dysregulated in rosacea-prone skin.

Topical ivermectin 1% cream addresses this component directly — it reduces Demodex mite density while simultaneously suppressing the downstream inflammatory cascade. A 2025 NRS-funded study confirmed that ivermectin also alters the facial skin microbiome, increasing populations of beneficial Staphylococcus epidermidis strains with anti-inflammatory properties.^[6] This combined mechanism likely explains why ivermectin consistently outperforms other topical agents for papulopustular disease.

The role of Demodex does not mean rosacea is simply a mite infestation. Plenty of patients with high Demodex counts have minimal rosacea, and some rosacea patients have relatively normal mite densities. The mites are one aggravating factor within a more complex inflammatory picture involving vascular dysregulation, innate immune dysfunction, and environmental triggers.

Identifying and Avoiding Your Triggers

Trigger avoidance is the single most cost-effective thing a rosacea patient can do. No medication works as well as it should if the provocative factors remain unaddressed. The NRS has documented the most common triggers across thousands of patients.^[2]

Top Rosacea Triggers

• Sun exposure — UV radiation is the most frequently reported trigger. Daily broad-spectrum SPF 30+ sunscreen (physical/mineral formulations with zinc oxide or titanium dioxide are better tolerated) is non-negotiable.
• Alcohol — especially red wine, beer, bourbon, and champagne. The vasodilatory effect of alcohol is direct and dose-related. Even small amounts can trigger significant flushing in susceptible patients.
• Spicy foods — capsaicin activates transient receptor potential (TRP) channels on sensory neurons in the skin, causing neurogenic vasodilation and flushing. Hot sauces, chili peppers, and paprika are common culprits.
• Heat and temperature extremes — hot baths, saunas, steam rooms, exercise in high heat, and even hot beverages. Core body temperature elevation is a reliable trigger for most patients.
• Cold and wind — temperature extremes in both directions can provoke flares.
• Emotional stress and anxiety — neurogenic flushing pathways link psychological stress to cutaneous vascular response.
• Histamine-rich foods — aged cheeses, processed meats, red wine, vinegar, and certain fermented foods contain histamine that can amplify vascular reactivity.
• Skincare products with alcohol, witch hazel, or fragrance — these are common irritants in otherwise benign-looking products.

Rosacea vs. Acne vs. Lupus

Getting the diagnosis right matters because these three conditions look similar but require fundamentally different management. Treating rosacea with standard acne regimens (benzoyl peroxide in high concentrations, astringents, retinoids at full strength) can dramatically worsen symptoms. Missing lupus has serious medical consequences.

Rosacea vs. Acne Vulgaris

The most reliable distinguishing feature: rosacea never produces comedones (blackheads or whiteheads). If you see comedones, think acne, not rosacea. Other differences:

Rosacea vs. Lupus (Systemic Lupus Erythematosus — Malar Rash)

The malar butterfly rash of lupus erythematosus can look remarkably similar to ETR rosacea. Both cause bilateral facial redness across the cheeks and nose. The key differentiators are location, associated symptoms, and laboratory findings:

• Nasolabial fold involvement: Rosacea involves the nasolabial folds. The lupus malar rash characteristically spares them, staying on the raised cheekbone area.
• Systemic symptoms: Lupus causes joint pain, fatigue, fever, oral ulcers, hair loss, and kidney disease. Rosacea is confined to skin and eyes.
• Telangiectasia and papules: Visible blood vessels and pus-filled bumps are common in rosacea. The lupus rash is typically flat or slightly raised without pustules or prominent telangiectasia.
• Sun behavior: Both worsen with sun exposure, but the lupus rash is more photosensitive and can trigger systemic flares.
• Duration: The lupus malar rash tends to be more persistent; rosacea flares and fades more predictably with triggers.

Ocular Rosacea: The Often-Overlooked Subtype

I want to spend time on this because it is genuinely underdiagnosed — and missing it can cause real, lasting harm to a patient's vision.

Ocular rosacea affects up to 58% of people with cutaneous rosacea, but because patients and physicians often focus on the skin, the eye involvement goes unaddressed.^[8] In about 15–20% of cases, ocular symptoms precede any visible skin changes — meaning patients may have been seeing eye doctors for years without the connection ever being made.

What Ocular Rosacea Looks Like

The primary mechanism is meibomian gland dysfunction (MGD) — the meibomian glands along the eyelid margin become inflamed and produce abnormally thick secretions that obstruct the gland openings. This disrupts the lipid layer of the tear film, leading to rapid evaporation and dry eye disease. Over time, meibomian gland atrophy can occur.

Symptoms and signs include:

• Gritty, burning, or foreign body sensation in the eyes
• Redness and telangiectasia along the eyelid margins
• Crusting or flaking at the base of the eyelashes (blepharitis)
• Recurring styes or chalazia (eyelid lumps)
• Chronic dry eye with intermittent watering
• Light sensitivity (photophobia)
• Conjunctival redness and occasional conjunctivitis
• In severe untreated cases: corneal vascularization, scarring, or ulceration

Management of Ocular Rosacea

Treatment is graded by severity:

• Mild: Warm compresses applied to the closed eyelids for 5–10 minutes twice daily, followed by gentle eyelid margin cleansing with a diluted baby shampoo or commercially available eyelid cleanser. Artificial tears for lubrication. Omega-3 fatty acid supplements have supportive evidence for improving meibomian gland secretion quality.^[4]
• Moderate: Topical cyclosporine eye drops (Restasis) twice daily to reduce ocular surface inflammation. Ophthalmic azithromycin applied to the eyelid margins. Oral doxycycline (40 mg modified-release or low-dose standard) is highly effective for ocular rosacea — this is one context where systemic treatment is often necessary even for milder skin disease.^[8]
• Severe / corneal involvement: Ophthalmology referral is required. IPL applied to the periocular area has shown benefit for meibomian gland function in rosacea patients. Corneal ulcers or vascularization need specialist management immediately.

The practical takeaway: if your eyes feel chronically irritated, gritty, or dry and you have any degree of facial redness, mention both sets of symptoms to your physician. They may be the same disease.

Laser and IPL for Persistent Redness and Telangiectasia

Medications manage inflammation and reduce flares, but they cannot eliminate established telangiectasia (permanently dilated blood vessels visible under the skin) or reverse significant background erythema. For these features, laser and intense pulsed light (IPL) therapy offer the most durable results.^[1]

How These Treatments Work

Laser and IPL devices target oxyhemoglobin in superficial blood vessels using selective photothermolysis — energy is absorbed by the red pigment in the vessel, generating heat that damages the vessel wall without harming surrounding tissue. The damaged vessel is then reabsorbed by the body over several weeks.

Devices Used in Rosacea

• Pulsed-dye laser (PDL, 585–595 nm): The most studied device for rosacea-associated erythema and telangiectasia. Targets oxyhemoglobin precisely. Multiple sessions (typically 3–6) spaced 4–6 weeks apart are standard. Also shown to reduce Demodex mite density and perirosacea inflammation in some studies.
• Intense pulsed light (IPL): Delivers multiple wavelengths rather than a single laser wavelength. Treats both erythema and the background redness of ETR. Generally gentler on the skin — more sessions are needed but patient satisfaction is high. Also FDA-cleared for ocular rosacea symptoms via periocular application.
• KTP laser (532 nm) and Nd:YAG laser (1064 nm): Options for telangiectasia and deeper vessels that PDL may not fully reach.
• CO2 and Er:YAG lasers: Used for phymatous changes and rhinophyma — ablative lasers that remove and reshape excess tissue.

These procedures require a board-certified dermatologist or trained laser specialist with experience in facial vascular treatments. Results are not permanent — the tendency for new vessel growth continues, and maintenance sessions are typically needed every 1–2 years. Patients with darker skin tones (Fitzpatrick types V–VI) require more conservative settings and careful device selection to minimize post-inflammatory changes.

Telehealth Dermatology for Rosacea

Rosacea is well-suited for telehealth evaluation. The diagnosis is primarily visual — central facial erythema, papules, and pustules are assessed reliably from high-quality photographs or a video visit. A board-certified physician can confirm the clinical picture, screen for red flags, prescribe topical or oral treatment, and provide a complete trigger management plan — all without an in-office visit.^[7]

A 2024 retrospective study from UPMC found that asynchronous photo-based teledermatology produced diagnostic concordance and treatment recommendations comparable to in-person dermatology visits for rosacea patients, with combination topical/oral therapy (metronidazole, sulfacetamide sodium-sulfur, and doxycycline) prescribed at similar rates across both settings.^[7]

What Telehealth Can Manage Well

• Classic papulopustular or erythematotelangiectatic rosacea with typical central facial features
• First-time rosacea diagnosis with photo confirmation
• Prescription and monitoring of topical agents (ivermectin, metronidazole, azelaic acid, brimonidine)
• Initiating and monitoring low-dose doxycycline 40 mg (Oracea)
• Follow-up visits and treatment adjustments for established rosacea
• Trigger counseling and skincare guidance
• Distinguishing rosacea from acne based on history and photographic assessment

When In-Person or Specialist Care Is Needed

• Ocular rosacea with eye pain, vision changes, or corneal involvement — ophthalmology referral
• Rhinophyma or significant phymatous changes — surgical dermatology
• Refractory disease requiring isotretinoin — in-person dermatology for iPLEDGE enrollment and monitoring
• Laser or IPL treatment for telangiectasia — in-person procedure
• Systemic symptoms suggesting lupus — rheumatology evaluation

If you have questions about whether your symptoms are appropriate for a telehealth evaluation, contact the TeleDirectMD team at 678-956-1855 or contact@teledirectmd.com.

Putting It Together: A Practical Treatment Framework

Here is how I approach rosacea management in clinical practice, using the phenotype-based model:

All patients with rosacea should use a mineral-based sunscreen (SPF 30 or higher) every morning regardless of weather, a gentle fragrance-free cleanser, and a simple non-irritating moisturizer. Stripping the skin barrier with harsh products makes every phenotype worse.

Frequently Asked Questions